- Protocol Short Name and Number: ECOG-ACRIN EA4151 MCL, 1601
- Protocol Long Name: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
- Key Personnel
- BMT CTN # 1601 Protocol Chair: Timothy Fenske, MD
- BMT CTN # 1601 Chair: Matthew Lunning, MD
- BMT CTN # 1601 Protocol Coordinator: Christiana Samuel, csamuel@ecog-acrin.org
- BMT CTN # 1601 Protocol Coordinator: Amy Foley, afoley@nmdp.org
- Keywords: Auto Transplant, Autologous Hematopoietic Cell Transplant, HCT, Autologous Transplant, Auto, Rituximab, Mantle Cell Lymphoma, MCL
Note: For the ECOG-ACRIN EA4151/BMT CTN 1601 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via their NCTN group. BMT CTN Centers will receive both NCTN and BMT CTN accrual credits. The protocol may be accessed through the CTSU website: https://www.ctsu.org For questions about the study and how to participate, contact the ECOG-ACRIN protocol coordinator, Haleigh Wetzel, at hwetzel@ecog-acrin.org or 857-504-2900, or the CTSU Help Desk at ctsucontact@westat.com or 1 888 823-5923.